The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in question ...

Although significant advances have been made in the pharmacologic and device-based treatment of HF, our understanding of the full range of the signaling and genomic mechanisms involved in HF ...

Please provide your email address to receive an email when new articles are posted on . CuraSen Therapeutics has announced positive data from a phase 2a study of its combination adrenergic activator, ...

Noradrenaline is a neuromodulator secreted in the brain depending on behavioral context and physiological states of animal, influencing a wide range of physiological functions by modulating brain ...

Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...

This study is led by Dr. Han Xiao (Department of cardiology and institute of vascular medicine, Peking university third hospital). Rapid over-activation of β-adrenergic receptors (β-AR) following ...

Dr. Olivier answers the question: 'What Are Adrenergic Agonists?' Aug. 24, 2009— -- Question: What are adrenergic agonists, when are they used to treat glaucoma, and what are the risks/benefits?

Researchers in Japan have discovered that the adrenergic nervous system controls when white blood cells circulate through the body, boosting the immune response by retaining T and B cells in lymph ...

Researchers have made a significant discovery about how the gut microbiome interacts with cells to cause cardiovascular disease. The study found phenylacetylglutamine (PAG), produced by gut bacteria ...